Cited by 117Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Open access

Kosoglou, Teddy, Meyer, Ingo, Veltri, Enrico P., Statkevich, Paul, Yang, Bo, Zhu, Yali, Mellars, Lillian, Maxwell, Stephen E., Patrick, James E., Cutler, David L., Batra, Vijay K., Affrime, Melton B.·2002·British Journal of Clinical Pharmacology

DOI 10.1046/j.1365-2125.2002.01633.xPMC PMC1874429

Open this paper in CoChat — free account Open PDF

Abstract

Aims The primary aims of these two single‐centre, randomized, evaluator‐blind, placebo/positive‐controlled, parallel‐group studies were to evaluate the potential for pharmacodynamic and pharmacokinetic interaction between ezetimibe 0.25, 1, or 10 mg and simvastatin 10 mg (Study 1), and a pharmacodynamic interaction between ezetimibe 10 mg and simvastatin 20 mg (Study 2). Evaluation of the tolerance of the coadministration of ezetimibe and simvastatin was a secondary objective. Methods Eighty‐two healthy men with low‐density lipoprotein cholesterol (LDL‐C) ≥130 mg dl−1 received study drug once daily in the morning for 14 days. In Study 1 (n=58), five groups of 11–12 subjects received simvastatin 10 mg alone, or with ezetimibe 0.25, 1, or 10 mg or placebo. In Study 2 (n=24), three groups of eight subjects received simvastatin 20 mg alone, ezetimibe 10 mg alone, or the combination. Blood samples were collected to measure serum lipids in both studies. Steady‐state pharmacokinetics of simvastatin and its β‐hydroxy metabolite were evaluated in Study 1 only. Results In both studies, reported side‐effects were generally mild, nonspecific, and similar among treatment groups. In Study 1, there were no indications of pharmacokinetic interactions between simvastatin and ezetimibe. All active treatments caused statistically significant (P<0.01) decreases in LDL‐C concentration vs placebo from baseline to day 14. The coadministration of ezetimibe and simvastatin caused a dose‐dependent reduction in LDL‐C and total cholesterol, with no apparent effect on high‐density lipoprotein cholesterol (HDL‐C) or triglycerides. The coadministration of ezetimibe 10 mg and simvastatin 10 mg or 20 mg caused a statistically (P<0.01) greater percentage reduction (mean −17%, 95% CI −27.7, −6.2, and −18%, −28.4, −7.4, respectively) in LDL‐C than simvastatin alone. Conclusions The coadministration of ezetimibe at doses up to 10 mg with simvastatin 10 or 20 mg daily was well tolerated and caused a significant additive reduction in LDL‐C compared with simvastatin alone. Additional clinical studies to assess the efficacy and safety of coadministration of ezetimibe and simvastatin are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.2002.01633.x

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Pharmacokinetics
Gibaldi, M., & Perrier, D. G. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098

Show all 52 references

Research works printed but not linked: 5

Zhu Y, 2000, Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo, Clin Pharmacol Ther, 67, 152
Zhu Y, 2000, Pharmacokinetics of ezetimibe in rats, dogs, and humans, AAPS Pharm Sci Supplement, 2, 2660
Kosoglou T, 2001, Multiple‐dose safety and pharmacokinetics of ezetimibe in adolescent children, Clin Pharmacol Ther, 69, P52
Kosoglou T, 2001, Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin, J Am Coll Cardiol, 37, 229A
10.1111/j.1525-1373.2000.22524.x · DOI

Sorted by citations

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., Mcgarry, T. F., Bettis, R. B., Melani, L., Lipka, L., LeBeaut, A., Suresh, R., Sun, S. H., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 557
Self-citation
Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia
Gagné, C., Gaudet, D., & Bruckert, É. (2002) · Circulation · doi:10.1161/01.cir.0000018744.58460.62 · Cited by 480
Ezetimibe
Kosoglou, T., Statkevich, P., Johnson‐Levonas, A. O., Paolini, J. F., Bergman, A. J., & Alton, K. B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544050-00002 · Cited by 479
Self-citation
Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 440
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
Kasiske, B. L., Cosío, B. G., Beto, J. A., Bolton, K., Chavers, B. M., Grimm, R. H., Levin, A., Masri, B. A., Parekh, R. S., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 313
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J. T., Musliner, T. A., McCabe, C. H., Veltri, E. P., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 294
Self-citation
Statin-fibrate combination therapy for hyperlipidaemia: a review
Wierzbicki, A. S., Mikhailidis, D. P., Wray, R., Schachter, M., Cramb, R., Simpson, W. G., & Byrne, C. D. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001668 · Cited by 156
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
Mikhailidis, D. P., Sibbring, G. C., Ballantyne, C. M., Davies, G. M., & Catapano, A. L. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x210507 · Cited by 150
Plant-based sterols and stanols in health & disease: “Consequences of human development in a plant-based environment?”
Plat, J., Baumgartner, S., Vanmierlo, T., Lütjohann, D., Calkins, K. L., Burrin, D. G., Guthrie, G. J., Thijs, C. T., Velde, A. A. T., Vreugdenhil, A. C. E., et al. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.02.003 · Cited by 138
Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated andNpc1l1−/−mice
Labonté, E. D., Camarota, L. M., Rojas, J. C., Jandacek, R. J., Gilham, D., Davies, J. P., Ioannou, Y. A., Tso, P., Hui, D. Y., & Howles, P. N. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90275.2008 · Cited by 114
Ezetimibe: A Selective Cholesterol Absorption Inhibitor
Nutescu, E. A., & Shapiro, N. L. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.14.1463.31942 · Cited by 111
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“Ezetimibe selectively inhibits the absorption of cholesterol in the small intestine [by interfering with the Niemann-Pick C1-like 1 protein (NPC1L1)] without modifying uptake of other nutrients and vitamins [56, 57].”
Background
Comparative effects of lipid-lowering therapies
Davidson, M. H., & Toth, P. P. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.007 · Cited by 106
Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Guideline For Stable Coronary Artery Disease
César, L. A. M., Ferreira, J., Armaganijan, D., Gowdak, L. H. W., Mansur, A. D. P., Bodanese, L., Sposito, A. C., Sousa, A. C., Aj, C., Markman, B., et al. (2014) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2014s004 · Cited by 92
Safety and efficacy of ezetimibe: A meta-analysis
Savarese, G., De Ferrari, G. M., Rosano, G. M. C., & Perrone-Filardi, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.103 · Cited by 88
Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor
Jeu, L., & Cheng, J. W. M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80281-3 · Cited by 84
Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79
Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients
Gaudiani, L., Lewin, A., Meneghini, L., Perevozskaya, I. T., Plotkin, D. J., Mitchel, Y., & Shah, S. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00420.x · Cited by 73
Pharmacodynamic interaction between ezetimibe and rosuvastatin
Kosoglou, T., Statkevich, P., Yang, B., Suresh, R., Zhu, Y., Boutros, T., Maxwell, S. E., Tiessen, R. G., & Cutler, D. L. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004213 · Cited by 71
Self-citation
Ezetimibe-associated adverse effects: what the clinician needs to know
Florentin, M., Liberopoulos, E. N., & Elisaf, M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01592.x · Cited by 64
Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*
Kosoglou, T., Statkevich, P., Fruchart, J., Pember, L. J. C., Reyderman, L., Cutler, D. L., Guillaume, M., Maxwell, S. E., & Veltri, E. P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125004277 · Cited by 61
Self-citation
Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats
van Heek, M., Farley, C., Compton, D. S., Hoos, L. M., Smith‐Torhan, A., & Davis, H. R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705187 · Cited by 60
A Retrospective Analysis of Ezetimibe Treatment in Renal Transplant Recipients
Buchanan, C., Smith, L. F., Corbett, J., Nelson, E. W., & Shihab, F. S. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01263.x · Cited by 56
Managing dyslipidemia in the high-risk patient
Stein, E. A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02229-4 · Cited by 50
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe
Daskalopoulou, S. S., & Mikhailidis, D. P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x89856 · Cited by 48
Pharmacology of ezetimibe
VANHEEK, M. (2002) · European Heart Journal Supplements · doi:10.1016/s1520-765x(02)90076-3 · Cited by 46
Drug interactions
Boobis, A. R., Watelet, J., Whomsley, R., Benedetti, M. S., Demoly, P. M., & Tipton, K. F. (2009) · Drug Metabolism Reviews · doi:10.1080/10837450902891550 · Cited by 46
Ezetimibe – a new approach in hypercholesterolemia management
Suchy, D., Łabuzek, K., Stadnicki, A., & Okopień, B. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70698-3 · Cited by 44
Ezetimibe: a novel option for lowering cholesterol
Davidson, M. H. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.1.11 · Cited by 43
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
Krishna, R., Garg, A. X., Jin, B., Keshavarz, S., Bieberdorf, F. A., Chodakewitz, J., & Wagner, J. A. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03385.x · Cited by 42
The power of statins: Aggressive lipid lowering
Stein, E. A. (2003) · Clinical Cardiology · doi:10.1002/clc.4960261506 · Cited by 41
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus*
Constance, C. M., Westphal, S., Chung, N., Lund, M., Sisk, C. M., Johnson‐Levonas, A. O., Massaad, R., & Allen, C. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00725.x · Cited by 40
Ezetimibe: efficacy and safety in clinical trials
Ballantyne, C. M. (2002) · European Heart Journal Supplements · doi:10.1016/s1520-765x(02)90077-5 · Cited by 38
Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview
Gazi, I. F., & Mikhailidis, D. P. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.6.851 · Cited by 36
Ezetimibe: A First‐in‐Class, Novel Cholesterol Absorption Inhibitor
Lipka, L. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00123.x · Cited by 34
Pleiotropic Effects With Equivalent Low-density Lipoprotein Cholesterol Reduction: Comparative Study Between Simvastatin and Simvastatin/Ezetimibe Coadministration
de Araújo, D. B., Bertolami, M. C., Ferreira, W. P., Abdalla, D. S. P., Faludi, A. Á., Nakamura, Y., & Bricharello, L. P. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181bfb1a2 · Cited by 33
Ezetimibe for Management of Hypercholesterolemia
Mauro, V. F., & Tuckerman, C. E. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c209 · Cited by 33
Simvastatin‐Ezetimibe‐Induced Hepatic Failure Necessitating Liver Transplantation
Tuteja, S., Pyrsopoulos, N., Wolowich, W. R., Khanmoradi, K., Levi, D., Selvaggi, G., Weisbaum, G. S., Tzakis, A. G., & Schiff, E. R. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.9.1188 · Cited by 30
Optimal management of hyperlipidemia in primary prevention of cardiovascular disease
Raza, J. A., Babb, J. D., & Movahed, A. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.07.039 · Cited by 30
Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study
Bissonnette, S., Habib, R., Sampalis, F. S., Boukas, S., & Sampalis, J. S. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70319-1 · Cited by 27
Combination therapy in the management of complex dyslipidemias
Davidson, M. H., & Toth, P. P. (2004) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000137221.16160.b9 · Cited by 27
Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia
Yoon, H. S., Kim, S. H., Kim, J. K., Ko, S. H., Ko, J. E., Park, S. J., Park, M. G., Lee, J. H., & Hyon, M. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p511 · Cited by 26
<![CDATA[Diretrizes de doen�a coronariana cr�nica angina est�vel]]>
C�sar, L. A. M., Mansur, A. D. P., Armaganijan, D., Amino, J. G. D. C., de Sousa, A. S., Sim�o, A. F., Brito, A. X., Caramelli, B., Vianna, C. B., Pastore, C. A., et al. (2004) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2004002100001 · Cited by 27
Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease
Nakamura, A., Sato, K., Kanazawa, M., Kondo, M., Endo, H., Takahashi, T., & Nozaki, E. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1319-x · Cited by 25
Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin
Kosoglou, T., Statkevich, P., Meyer, I., Cutler, D. L., Musiol, B., Yang, B., Zhu, Y., Maxwell, S. E., & Veltri, E. P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003872 · Cited by 23
Self-citation
Colesterol LDL, cuanto más bajo mejor
Pedro‐Botet, J., & Pintó, X. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.10.003 · Cited by 23
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 24
Ezetimibe/Simvastatin
Murdoch, D. L., & Scott, L. J. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404060-00009 · Cited by 21
Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management
Sun, L., Wolska, A. T., Amar, M. J., Zubirán, R., & Remaley, A. T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad153 · Cited by 22
Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI–MS/MS and its application to a pharmacokinetic study
Karanam, S. R., Katakam, P., Chandu, B. R., Hwisa, N. T., & Adiki, S. K. (2013) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2013.08.002 · Cited by 19
Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study
Fras, Z., & Mikhailidis, D. P. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802303772 · Cited by 19
Lipids in health and disease
Shepherd, J. (2004) · Biochemical Society Transactions · doi:10.1042/bst0321051 · Cited by 19
Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan
Lin, C.-F., Gau, C., Wu, F. L., Hsiao, F., Bai, C., & Shen, L. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.08.002 · Cited by 16
Identification and treatment of individuals at high risk of coronary heart disease.
Stein, E. (2002) · American Journal of Medicine · doi:10.1016/s0002-9343(02)01084-7 · Cited by 17
Combination therapy: its rationale and the role of ezetimibe
Stone, N. J. (2002) · European Heart Journal Supplements · doi:10.1016/s1520-765x(02)90078-7 · Cited by 17
Ezetimibe/simvastatin (INEGY™) in the treatment of hyperlipidaemia
Kastelein, J. J. P., & Sankatsing, R. R. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00737.x · Cited by 16
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe
Reyderman, L., Kosoglou, T., Cutler, D. L., Maxwell, S. E., & Statkevich, P. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x46386 · Cited by 15
Self-citation
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers*
Reyderman, L., Kosoglou, T., Boutros, T., Seiberling, M., & Statkevich, P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2547 · Cited by 15
Self-citation
Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies
Sasidharan, A., Sajith Kumar, S., Jagadeesh, K. V., Natarajan, M., & Bagepally, B. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264563 · Cited by 14
Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe
Patiño-Rodríguez, O., Torres-Roque, I., Martínez-Delgado, M., Escobedo-Moratilla, A., & Pérez‐Urizar, J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00261 · Cited by 14
Lack of clinically relevant drug–drug interactions when dalcetrapib is co‐administered with ezetimibe
Derks, M., Abt, M., & Phelan, M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03763.x · Cited by 13
Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination
Han, S., Yang, W.-H., Yin, J., Tao, H., & Zhang, L. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00317-1 · Cited by 12
[Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review].
Franco, D., Henao, Y., Monsalve, M., Gutiérrez, F., Hincapié-García, J. A., & Amariles, P. (2013) · PubMed · doi:10.7399/fh.2013.37.6.1077 · Cited by 12
Microenvironment factors do not afford myeloma cell lines protection from simvastatin
Osadchy, A., Drucker, L., Radnay, J., Shapira, H., & Lishner, M. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00284.x · Cited by 12
Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination Tablet
Chu, N., Chen, W., Xu, H., & Li, X. (2012) · Clinical Drug Investigation · doi:10.1007/s40261-012-0013-5 · Cited by 12
The Antilipidemic Effects of Ezetimibe in Patients With Diabetes
Stroup, J. S., Kane, M. P., & Busch, R. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2958-a · Cited by 12
Ezetimibe: A Review of Analytical Methods for the Drug Substance, Pharmaceutical Formulations and Biological Matrices
Rocha, L. P., Cabral, L. M., Pinto, E. C., & de Sousa, V. P. (2020) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2020.1857222 · Cited by 11
Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease
Ábel, T., Fehér, J., Dinya, E., El‐Din, M. G., & Kovács, A. D. (2009) · Orvosi Hetilap · doi:10.1556/oh.2009.28624 · Cited by 11
Cholesterol Absorption and the Metabolic Syndrome
Berglund, L., & Hyson, D. A. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000087145.71160.15 · Cited by 10
An ezetimibe–policosanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.051 · Cited by 9
Simvastatin–Ezetimibe enhances growth factor expression and attenuates neuron loss in the hippocampus in a model of intracerebral hemorrhage
Wang, K., Liang, C., Yeh, L., Liu, K., Chen, C., Chen, J., Chen, H., & Wang, H. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12635 · Cited by 8
Inhibición selectiva de la absorción de colesterol: una nueva perspectiva en el tratamiento de la hipercolesterolemia
Lima, J., Fonollosa‐Pla, V., & Chacón, P. M. (2005) · Medicina Clínica · doi:10.1157/13076400 · Cited by 8
The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic
Pearson, G. J., Francis, G. A., Romney, J. S., Gilchrist, D. M., Opgenorth, A., & Gyenes, G. T. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70313-0 · Cited by 8
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients
Strony, J. T., Hoffman, R., Hanson, M. E., & Veltri, E. P. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.008 · Cited by 8
Self-citation
The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus
Sharifi, F., Hojeghani, N., Mazloomzadeh, S., & Shajari, Z. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-24 · Cited by 6
The Possible Protective Effects of Inegy versus Cinnamon Oil on the Aorta of Albino Rats with Experimentally Induced Hyperlipidemia
Safi, M. M. (2015) · International Journal of Clinical and Experimental Medical Sciences · doi:10.11648/j.ijcems.20150104.12 · Cited by 6
Simvastatin Induces Death of Multiple Myeloma Cell Lines
Gronich, N., Drucker, L., Shapiro, H., Radnay, J., Yarkoni, S., & Lishner, M. (2004) · Journal of Investigative Medicine · doi:10.1177/108155890405200534 · Cited by 6
A Case Study of Single‐Pill Combination Therapy: The Ezetimibe/Simvastatin Combination for Treatment of Hyperlipidemia
Huang, X., & Chen, D. Y. ‐. (2012) · ChemMedChem · doi:10.1002/cmdc.201200287 · Cited by 5
Discovery of the cholesterol absorption inhibitor, ezetimibe
Ganellin, C. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397176-0.00015-7 · Cited by 5
A review of lipid-modifying drugs used alone and in combination
Kwiterovich, P. O. (2005) · Advanced studies in medicine · Cited by 5
Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin
Srinivas, N. R. (2016) · Drug Research · doi:10.1055/s-0042-106289 · Cited by 4
Newer pharmaceutical agents to treat lipid disorders
Davidson, M. H. (2003) · Current Cardiology Reports · doi:10.1007/s11886-003-0108-y · Cited by 4
The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia
Saseen, J. J., Williams, S. A., Valuck, R. J., Donnell, J. C. O., & McDonough, K. L. (2005) · Disease Management & Health Outcomes · doi:10.2165/00115677-200513040-00004 · Cited by 4
The place of ezetimibe in clinical practice
Weston, C. F. M. (2003) · Hospital Medicine · doi:10.12968/hosp.2003.64.8.2262 · Cited by 3
Low-density lipoprotein cholesterol lowering by adding ezetimibe to statin is associated with improvement of postprandial hyperlipidemia in diabetic patients with coronary artery disease
Nakamura, A., Kajitani, S., Monma, Y., Sato, K., Terui, Y., Kanazawa, M., Noda, K., Endo, H., Takahashi, T., & Nozaki, E. (2016) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2016.11.001 · Cited by 2
Drugs that Affect Lipid Metabolism
Ohashi, W., & Hattori, Y. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-63407-8.00044-7 · Cited by 2
Pharmacological Therapy for Cardiovascular Disease
Davidson, M. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_7 · Cited by 2
Beneficios de la terapia combinada en la hiperlipemia
Padial, L. R., López, J. A., & Salicio, E. R. (2006) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(06)75330-4 · Cited by 1
Pharmacokinetics and Bioequivalence of Fixed‐Dose Combination of Simvastatin and Ezetimibe Tablets: A Randomized, Crossover, Open‐Label Study in Healthy Volunteers
Leong, C. W., Yee, K. M., Rani, T. A., Lau, K. J., Ahmad, S., Amran, A., Hassan, F. W. M., & Kumar, N. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1411 · Cited by 1
Medical Management of Stable Coronary Artery Disease
Boden, W. E. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch25 · Cited by 1
Combination of a Sterol Absorption Inhibitor and Cardiovascular Agents for the Treatment of Dyslipidemia
Chrysohoou, C. A., & Singh, S. N. (2006) · Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) · doi:10.2174/157489006775244218 · Cited by 1
Inhibidores de la absorción del colesterol
Boix, E., & Pico, A. M. (2005) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(05)74800-2 · Cited by 1
Ezetimibe and Cholesterol Absorption
Oswald, S., & Siegmund, W. (2011) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse448 · Cited by 1
Inegy – effective combination treatment to target LDL-C levels
Croom, K. F. (2008) · Drugs in Context · doi:10.7573/dic.212217 · Cited by 1
Optimierte Cholesterinsenkung
von Hodenberg, E. (2005) · Der Internist · doi:10.1007/s00108-005-1412-y · Cited by 1
El papel del bloqueo de la absorción intestinal del colesterol en el tratamiento de la hipercolesterolemia
Diz-Lois, F. (2004) · Revista Clínica Española · doi:10.1016/s0014-2565(04)71543-x · Cited by 1
Ezetimibe
Cada, D. J., Levien, T. L., & Baker, D. E. (2003) · Hospital Pharmacy · doi:10.1177/001857870303800401 · Cited by 1

Authors: Kosoglou, T., Meyer, I., Veltri, E. P., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S. E., Patrick, J. E., Cutler, D. L., Batra, V. K., & Affrime, M. B.
Affiliations: IQVIA (United States) (US)
Corresponding author: Kosoglou, Teddy
ORCID: Statkevich, Paul
Yang, Bo
Zhu, Yali
Maxwell, Stephen E.
Cutler, David L.
Venue: British Journal of Clinical Pharmacology
Publisher: Wiley
Published: 2002-09
Volume: 54
Issue: 3
Pages: 309-319
ISSN: 0306-5251 (ISSN-L)
1365-2125
DOI: 10.1046/j.1365-2125.2002.01633.x
PMC: PMC1874429
OpenAlex: W1498903994
Semantic Scholar: 72c4048e09bae02d9558d6f422ca2effd4944f2f
Cited by: 117
References: 52
Citations by year: 2026: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2020: 3 · 2019: 6 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 5 · 2013: 6 · 2012: 4
FWCI: 14.29
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 17 d)
Locations: British Journal of Clinical Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: ezetimibe, simvastatin, drug-drug interactions, pharmacodynamic interactions, pharmacokinetic interactions, LDL cholesterol, total cholesterol, statins, cholesterol absorption inhibitors, serum lipids, hypercholesterolemia, dose dependence, healthy men, healthy women, healthy children, healthy older adults, healthy pregnant women
MeSH terms: Ezetimibe, Administration, Oral, Adult, Anticholesteremic Agents, Azetidines, Biological Availability, Dose-Response Relationship, Drug, Drug Combinations, Drug Interactions, Humans, Cholesterol, LDL, Male, Middle Aged, Body Mass Index, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks